Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Rani Therapeutics Holdings (RANI) over the last 5 years, with Q3 2025 value amounting to -$9000.0.

  • Rani Therapeutics Holdings' Gains from Investment Securities changed N/A to -$9000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $38000.0, marking a year-over-year decrease of 9919.68%. This contributed to the annual value of $4.7 million for FY2024, which is 282037.04% up from last year.
  • Per Rani Therapeutics Holdings' latest filing, its Gains from Investment Securities stood at -$9000.0 for Q3 2025.
  • Rani Therapeutics Holdings' 5-year Gains from Investment Securities high stood at $4.7 million for Q1 2024, and its period low was -$9000.0 during Q3 2025.
  • In the last 4 years, Rani Therapeutics Holdings' Gains from Investment Securities had a median value of $57000.0 in 2021 and averaged $752430.9.
  • In the last 5 years, Rani Therapeutics Holdings' Gains from Investment Securities soared by 371532.26% in 2024 and then plummeted by 9951.38% in 2025.
  • Over the past 4 years, Rani Therapeutics Holdings' Gains from Investment Securities (Quarter) stood at $85000.0 in 2021, then plummeted by 65.88% to $29000.0 in 2023, then surged by 16213.79% to $4.7 million in 2024, then plummeted by 100.19% to -$9000.0 in 2025.
  • Its Gains from Investment Securities was -$9000.0 in Q3 2025, compared to $24000.0 in Q2 2025 and $23000.0 in Q1 2025.